Efrat Ozeri-galai

Title: Efrat Ozeri-Galai: Innovator in CFTR Gene Modulation

Introduction

Efrat Ozeri-Galai is a notable inventor based in Jerusalem, Israel. He has made significant contributions to the field of genetic research, particularly in the modulation of the CFTR gene, which is crucial for cystic fibrosis treatment. His innovative work has the potential to impact therapeutic approaches for genetic disorders.

Latest Patents

Efrat Ozeri-Galai holds a patent titled "Restoration of the CFTR function by splicing modulation." This invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene. The patent includes compositions comprising these oligonucleotides and their uses, such as suppressing the inclusion of a cryptic exon between exon 22 and 23 due to the mutation 3849+10Kb C-to-T. This work is particularly relevant when used in combination with additional cystic fibrosis therapeutics.

Career Highlights

Throughout his career, Efrat has worked with prominent organizations, including Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Splisense Ltd. His experience in these companies has allowed him to advance his research and contribute to the scientific community.

Collaborations

Efrat has collaborated with notable colleagues, including Bat Sheva Kerem and Yifat Oren. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in genetic research.

Conclusion

Efrat Ozeri-Galai's work in CFTR gene modulation exemplifies the impact of innovative research on genetic therapies. His contributions are paving the way for advancements in the treatment of cystic fibrosis and other genetic disorders.